Silence Therapeutics
About Silence Therapeutics
Silence Therapeutics is a London-based biotech developing siRNA (short interfering RNA) medicines using its mRNAi GOLD platform.
Milestones
Milestones as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Leadership Team
Leadership as listed on sec.gov, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Steven Romano, M.D.
Products & Services
Products and services as listed on silence-therapeutics.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
mRNAi GOLD platform
Proprietary siRNA platform that silences disease-linked genes without permanently changing DNA.
Source: silence-therapeutics.comZerlasiran (SLN360)
Wholly owned siRNA in development to lower high lipoprotein(a), a genetic cardiovascular risk factor.
Source: silence-therapeutics.comDivesiran
Investigational siRNA for polycythaemia vera that silences TMPRSS6 to raise hepcidin levels.
Source: silence-therapeutics.comSLN312
Licensed to AstraZeneca; Silence will regain global rights after Phase 1 (announced March 2026).
Source: silence-therapeutics.comPipeline & Regulatory Record
What public registers list for Silence Therapeutics: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 10 Oct 2026.
Clinical trials 1 in our ClinicalTrials.gov registers
| Study | Phase | Status |
|---|---|---|
| Study to Assess SLN124 in Patients With Polycythemia Vera NCT05499013 · Polycythemia Vera |
Phase 1/2 | Active, closed |
How this is matched: register records are linked to this page by the organisation name they carry, here Silence Therapeutics plc. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports Silence Therapeutics plc files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $559,000 | $67.8m | >999% | −$88.6m | 10-K 2026 |
| Dec 2024 | $43.3m | $67.9m | 156.9% | −$45.3m | 10-K 2026 |
| Dec 2023 | $31.6m | $56.9m | 179.9% | −$54.2m | 10-K 2026 |
| Dec 2022 | $21.7m | $43.6m | 201.1% | −$50.3m | 10-K 2025 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.